Have Immatics insiders bought shares recently?

No open-market purchase by an insider of Immatics is on record in SEC filings since 2006.

Who is selling Immatics stock?

No open-market sale by an insider of Immatics (IMTX) was filed with the SEC in the last 90 days.

Do members of Congress trade IMTX?

No trade in Immatics (IMTX) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Immatics (IMTX) insider trading and stock trades

Q: When does Immatics report its next results?

Immatics's next results are expected on Mar 3, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at IMTX buy and sell in the last 90 days?Which members of Congress and which funds traded IMTX recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

IMTX price and disclosed activity

−36.0% (−$3.59) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

13F holdings, by quarter end

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Insider open-market trades, filed in the last 90 daysNoneFew or no Form 4 filings, see the note belowInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, quarter ending Jun 30, 20260 added · 2 cut2 followed funds; holdings as of the quarter end, filed by Aug 14, 2026Fund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Biological Products, (No Diagnostic Substances) company based in Tubingen, Germany. Foreign private issuer: reports on Form 20-F or 40-F.

Full company description

Biological Products, (No Diagnostic Substances) company based in Tubingen, Germany. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.

Last 12 months

−36.0%

S&P 500 +12.3% over the same dates

Market value

$857M

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 3.67M shares sold short (2.7% of shares outstanding), −2.1% vs the previous count, 3.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

The last year in context

Trading desk

Against the S&P 500 over the year

IMTX −30.5%S&P 500 fund (SPY) +10.4%

Since Nov 11, 2025, IMTX is down 30.5% and the index fund is up 10.4%: 41 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.

How much IMTX moves

A usual day: ±2.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14): 7.1%Average distance between the low and the high of a session, over the last 14.
Largest one-day fall: −14.2%Dec 5, 2025
Largest one-day rise: +16.1%Nov 12, 2025
Deepest fall of the year: −47.9%From the close of Dec 4, 2025 to Nov 5, 2026.
Days of 5% or more: 32Out of 252 sessions, in either direction.

End-of-day prices. These figures describe the past year and say nothing about what comes next.

On the public record for Immatics over the 12 months to Nov 14, 2026: 2 clinical trials.

When insiders usually buy

Last results

—

Next results, expected

Mar 3, 2027

after the market closes; the date can move until the company confirms it

Purchases after results

Not enough history

From Immatics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Immatics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.

Holders above 5%

Montanova Capital, LLC
Schedule 13G: passive · filed Nov 13, 2026 · 8.75M shares
5.8%

Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.

Late-stage clinical trials

1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in melanoma, cutaneous malignant, refractory cancer. The ones with the nearest registered primary completion date still ahead:

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

Latest

See everything

Fund moves

781KPrior-quarter shares · no longer reported

Filed 3mo ago

2 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.

More Official record

Fund moves

Want the short version?

Immatics

How this filing works

Questions about Immatics insider trading

IMTX price and disclosed activity

The last year in context

When insiders usually buy

Holders above 5%

Late-stage clinical trials

Latest

781KPrior-quarter shares · no longer reported

9.51MShares reported · -1.41M vs prior quarter

781KShares reported · +736K vs prior quarter

12.9MShares reported · +1.44M vs prior quarter

10.9MShares reported · -1.18M vs prior quarter

Other Biological Products, (No Diagnostic Substances) companies

The last year in context

Holders above 5%

Late-stage clinical trials

When insiders usually buy